Cerebrospinal fluid biomarkers for neurodegenerative disorders

Detalhes bibliográficos
Autor(a) principal: Videira, Rita Margarida Almeida Santos
Data de Publicação: 2013
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/25736
Resumo: Neurodegenerative diseases are one of the major world causes of morbidity and mortality, and giving the dramatic raise in life expectancy, they are reaching epidemic proportions. These disorders form a heterogeneous group, ranging from multi-factorial dementias to rare monogenic inherited proteopathies, but they all are progressive and so far lethal, since there are no disease-modifying therapies presently available. Therefore, major research efforts are in progress for developing effective therapies, but in order to achieve this goal there is an imperative need of consistent tools for diagnosis, prognosis and monitoring drug effects and efficacy. Biomarkers have the potential to respond to all these requirements and its research is a rapidly advancing field, supported by some cases of success for other diseases, in different fields like oncology and cardiology. Pathological alterations in the brain or central nervous system could be monitored by analysis of cerebrospinal fluid and several biomarkers in this fluid have been proposed. However, almost none have reached validation and for that reason they are still not used in clinical routine. Several problems regarding lack of longitudinal studies or reproducibility between reports are still waiting to be solved. In a near future this could happen by more intensive collaboration between research centers, industry and government in different countries, in joint initiatives. This review summarizes the most relevant CSF biomarker candidates for Alzheimer’s and Parkinson’s disease, Amyotrophic lateral sclerosis, Huntington’s and Machado Joseph disease. It also briefly passes through biomarker definitions and concepts, beyond the current limitations in this investigation area.
id RCAP_acee89c0f9727873c45eb5b4bb671e17
oai_identifier_str oai:estudogeral.uc.pt:10316/25736
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Cerebrospinal fluid biomarkers for neurodegenerative disordersDoenças neurodegenerativasBiomarcadoresNeurodegenerative diseases are one of the major world causes of morbidity and mortality, and giving the dramatic raise in life expectancy, they are reaching epidemic proportions. These disorders form a heterogeneous group, ranging from multi-factorial dementias to rare monogenic inherited proteopathies, but they all are progressive and so far lethal, since there are no disease-modifying therapies presently available. Therefore, major research efforts are in progress for developing effective therapies, but in order to achieve this goal there is an imperative need of consistent tools for diagnosis, prognosis and monitoring drug effects and efficacy. Biomarkers have the potential to respond to all these requirements and its research is a rapidly advancing field, supported by some cases of success for other diseases, in different fields like oncology and cardiology. Pathological alterations in the brain or central nervous system could be monitored by analysis of cerebrospinal fluid and several biomarkers in this fluid have been proposed. However, almost none have reached validation and for that reason they are still not used in clinical routine. Several problems regarding lack of longitudinal studies or reproducibility between reports are still waiting to be solved. In a near future this could happen by more intensive collaboration between research centers, industry and government in different countries, in joint initiatives. This review summarizes the most relevant CSF biomarker candidates for Alzheimer’s and Parkinson’s disease, Amyotrophic lateral sclerosis, Huntington’s and Machado Joseph disease. It also briefly passes through biomarker definitions and concepts, beyond the current limitations in this investigation area.2013info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttp://hdl.handle.net/10316/25736http://hdl.handle.net/10316/25736TID:201655284engVideira, Rita Margarida Almeida Santosinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-05-25T06:10:13Zoai:estudogeral.uc.pt:10316/25736Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:47:45.906743Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Cerebrospinal fluid biomarkers for neurodegenerative disorders
title Cerebrospinal fluid biomarkers for neurodegenerative disorders
spellingShingle Cerebrospinal fluid biomarkers for neurodegenerative disorders
Videira, Rita Margarida Almeida Santos
Doenças neurodegenerativas
Biomarcadores
title_short Cerebrospinal fluid biomarkers for neurodegenerative disorders
title_full Cerebrospinal fluid biomarkers for neurodegenerative disorders
title_fullStr Cerebrospinal fluid biomarkers for neurodegenerative disorders
title_full_unstemmed Cerebrospinal fluid biomarkers for neurodegenerative disorders
title_sort Cerebrospinal fluid biomarkers for neurodegenerative disorders
author Videira, Rita Margarida Almeida Santos
author_facet Videira, Rita Margarida Almeida Santos
author_role author
dc.contributor.author.fl_str_mv Videira, Rita Margarida Almeida Santos
dc.subject.por.fl_str_mv Doenças neurodegenerativas
Biomarcadores
topic Doenças neurodegenerativas
Biomarcadores
description Neurodegenerative diseases are one of the major world causes of morbidity and mortality, and giving the dramatic raise in life expectancy, they are reaching epidemic proportions. These disorders form a heterogeneous group, ranging from multi-factorial dementias to rare monogenic inherited proteopathies, but they all are progressive and so far lethal, since there are no disease-modifying therapies presently available. Therefore, major research efforts are in progress for developing effective therapies, but in order to achieve this goal there is an imperative need of consistent tools for diagnosis, prognosis and monitoring drug effects and efficacy. Biomarkers have the potential to respond to all these requirements and its research is a rapidly advancing field, supported by some cases of success for other diseases, in different fields like oncology and cardiology. Pathological alterations in the brain or central nervous system could be monitored by analysis of cerebrospinal fluid and several biomarkers in this fluid have been proposed. However, almost none have reached validation and for that reason they are still not used in clinical routine. Several problems regarding lack of longitudinal studies or reproducibility between reports are still waiting to be solved. In a near future this could happen by more intensive collaboration between research centers, industry and government in different countries, in joint initiatives. This review summarizes the most relevant CSF biomarker candidates for Alzheimer’s and Parkinson’s disease, Amyotrophic lateral sclerosis, Huntington’s and Machado Joseph disease. It also briefly passes through biomarker definitions and concepts, beyond the current limitations in this investigation area.
publishDate 2013
dc.date.none.fl_str_mv 2013
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/25736
http://hdl.handle.net/10316/25736
TID:201655284
url http://hdl.handle.net/10316/25736
identifier_str_mv TID:201655284
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133756056928256